Growth factor allows effective dose-intensive regimen in advanced breast cancer patients
Oncology 9(7): 684
1995
ISSN/ISBN: 0890-9091 PMID: 8924381 Document Number: 441219
Document emailed within 1 workday
Related Documents
de Graaf, H.; Willemse, P.H.; Sleijfer, D.T.; de Vries, E.G.; Van der Graaf, W.T.; Beukema, J.; Mulder, N.H. 1994: Effective conditioning regimen for premenopausal patients with advanced breast cancer Anticancer Research 14(6b): 2799-2804Bramwell, V.H.; Howell, A.; Scarffe, H.; Crowther, D.; Sellwood, R.A. 1982: VAP-cyclo: a short intensive regimen of chemotherapy for advanced breast cancer Cancer Treatment Reports 66(11): 1999-2000
Palumbo, A.; Triolo, S.; Baldini, L.; Callea, V.; Capaldi, A.; De Stefano, V.; Grasso, M.; Liberati, M.; Lotesoriere, C.; Marcenò, R.; Marmont, F.; Musto, P.; Petrucci, M.T.; Spriano, M.; Pileri, A.; Boccadoro, M. 2000: Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients Haematologica 85(5): 508-513
Pacetti, U.; Veltri, E.; Fattoruso, S.Ileana.Sara.; Cardillo, F.D'Assisi.; Evangelista, S.; Cognetti, F.; Fabi, A. 2013: Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer Anticancer Research 33(4): 1721-1724
Makino, H.; Iraha, M.; Manba, N.; Hashidate, H.; Shiotani, M. 2012: Utility of serum human epidermal growth factor receptor-2 extracellular domain(HER2 ECD)assessment in patients with advanced or recurrent breast cancer and those who received neoadjuvant therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(2): 237-240
Chitapanarux, I.; Lorvidhaya, V.; Kamnerdsupaphon, P.; Tharavichitkul, E.; Trakultivakorn, H.; Somwangprasert, A.; Sumitsawan, S.; Srisukho, S.; Watcharachan, K.; Sukthomya, V. 2006: Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(6): 761-766
Zhao, L.-d.; Li, J.-L.; Wang, Y.; Wang, B.; Wang, H.-Y.; Hao, X.-Z.; Cui, C.-X.; Zhang, X.-R.; Shi, Y.-K. 2011: Analysis of chemotherapeutic efficacy after a failed regimen of epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced non-small cell lung carcinoma Zhonghua Yi Xue Za Zhi 91(6): 366-369
Leonard, J.P. 2003: Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support Current Hematology Reports 2(6): 451-452
Donato, M.L.; Champlin, R.E.; Wharton, J.T.; Bodurka-Bevers, D.; Gershenson, D. 2000: Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer European Journal of Gynaecological Oncology 21(3): 241-244
Murayama, Y.; Mishima, Y. 1988: Effect of transforming growth factor-beta and epidermal growth factor on cell growth of human breast cancer Nihon Geka Gakkai Zasshi 89(2): 312
Taguchi, T.; Sakai, K.; Terasawa, T.; Wada, H. 1986: Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(9): 2820-2828
Martoni, A.; Cricca, A.; Guaraldi, M.; Covizzi, M.; Farris, A.; Pannuti, F. 1992: Weekly regimen of 5-FU vs 5-FU + intermediate dose folinic acid in the treatment of advanced colorectal cancer Anticancer Research 12(3): 607-612
Kawamura, M.; Nakano, S.; Kyoda, S.; Tabei, I.; Yoshida, K.; Takeyama, H. 2013: Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(7): 909-912
Rühl, U. 2000: Consolidation radiotherapy after high-dose chemotherapy and autologous bone marrow transplantation in patients with advanced breast cancer Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 176(4): 196-197
Imai, Y.; Leung, C.K.; Friesen, H.G.; Shiu, R.P. 1982: Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture Cancer Research 42(11): 4394-4398
Foekens, J.A.; Portengen, H.; van Putten, W.L.; Trapman, A.M.; Reubi, J.C.; Alexieva-Figusch, J.; Klijn, J.G. 1989: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer Cancer Research 49(24 Part 1): 7002-7009
Lee, J.E.; Chung, K.-W.; Han, W.; Kim, S.-W.; Kim, S.W.; Shin, H.J.; Bae, J.Y.; Noh, D.-Y. 2004: Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells Anticancer Research 24(6): 3961-3964
Shimizu, Y.; Nakayama, K.; Seimiya, Y.; Yamakawa, Y.; Koi, S.; Yokosuka, K.; Teshima, H.; Chen, J.T.; Fujimoto, I.; Yamauchi, K. 1991: Treatment of advanced or recurrent cervical cancer by a new BOMP regimen consisting of bleomycin, vincristine, mitomycin-C, and low-dose consecutive cisplatin Nihon Sanka Fujinka Gakkai Zasshi 43(5): 549-556
Cosmas, C.; Tsavaris, N.; Malamos, N.; Tsakonas, G.; Gassiamis, A.; Skopelitis, H.; Soukouli, G.; Polyzos, A.; Mylonakis, N.; Karabelis, A. 2005: Dose escalation of docetaxel and ifosfamide in patients with advanced breast cancer failing prior anthracyclines: mature results of a phase I-Ii study Journal of Buon: Official Journal of the Balkan Union of Oncology 10(3): 337-346
Kubota, O.; Onuki, Y.; Uchiyama, T.; Oishi, K.; Takeda, M. 2012: Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(5): 753-757